Good analysis regarding the SP,, except
early stage Bio buy out offers are a multiplier of the current SP, many Buyouts are circa 200% to 400% of the SP,, sure there are exceptions most of those are earning biotechs and Big Pharma buy them because they have the resources to scale them up, eg J & J have 11 thousand sales staff...
A 100% turn around on good news would only see BOT rise but still be below the years high considerably.
Most Investors here want to see greater returns than 10% to 20% but our insto would be grateful for a 20% return for "their shareholders"... so you can see the quagmire of the Insto with 139,000,000 shares to churn.
but as you rightly state ,,,,Time will Tell all
Good analysis regarding the SP,, except early stage Bio buy out...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.005(1.37%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.0¢ | $391.8K | 1.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 160000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 11013 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
